Skip to main content
Article thumbnail
Location of Repository

Independent Evaluation of Phase 1 of the Affordable Medicines Facility - malaria (AMFm), Multi-Country Independent Evaluation Final Report

By K Amfm Independent Evaluation Team: Hanson, C Goodman, S Tougher, A Mann, B Willey, F Arnold, Y Ye, R Ren and S Yoder

Abstract

The success of malaria control efforts depends on a high level of coverage in the use of effective antimalarials such as artemisinin-based combination therapies (ACTs). Although these anti-malarials have been procured in large amounts by countries, evidence suggests that ACT use still remains far below target levels. In response to this issue, the Affordable Medicines Facility – malaria (AMFm) hosted by the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) was set up. AMFm comprises three key elements: (i) price reductions through negotiations with ACT manufacturers; (ii) a buyer subsidy through a ‘co-payment’ for ACTs at the top of the global supply chain; and (iii) supporting interventions to promote appropriate use of ACTs. Examples of these supporting interventions include training providers and outreach to communities to promote ACT use. All ACTs subsidized through AMFm bear a green leaf logo on their packaging. The four main objectives of AMFm are to: (i) increase ACT affordability; (ii) increase ACT availability; (iii) increase ACT use, including among vulnerable groups; and (iv) “crowd out” oral artemisinin monotherapies, chloroquine and sulfadoxine-pyrimethamine (SP) by increasing the market share for ACTs

Publisher: ICF International and London School of Hygiene and Tropical Medicine
Year: 2012
OAI identifier: oai:researchonline.lshtm.ac.uk:2869474
Provided by: LSHTM Research Online

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.